Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.00 and traded as high as $0.21. Hemispherx BioPharma shares last traded at $0.21, with a volume of 747,915 shares trading hands.
Hemispherx BioPharma Stock Down 5.7 %
About Hemispherx BioPharma
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
See Also
- Five stocks we like better than Hemispherx BioPharma
- What is the NASDAQ Stock Exchange?
- 3 Legacy Tech Companies Reemerging as AI LeadersÂ
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
